About 93,900 results
Open links in new tab
  1. Schrödinger - Physics-based Software Platform for Molecular …

    Schrödinger is the scientific leader in developing state-of-the-art chemical simulation software for use in pharmaceutical, biotechnology, and materials research.

  2. Pipeline of Collaborative & Proprietary Drug Discovery Programs ...

    We are leveraging our computational platform and massive computing power to advance our proprietary programs both independently and in collaboration with leading biotech and …

  3. About us - Schrödinger

    Our mission is to improve human health and quality of life by transforming the way therapeutics and materials are discovered.

  4. Computational Platform for Molecular Discovery & Design

    Our physics-based computational platform integrates differentiated solutions for predictive modeling, data analytics, and collaboration to enable rapid exploration of chemical space.

  5. Schrödinger, Inc. - Investor Relations

    Nov 6, 2025 · Schrödinger is transforming the way therapeutics and materials are discovered. Learn more about our company.

  6. Our Team - Schrödinger

    Schrödinger’s collaborative leadership team is committed to achieving the best possible outcomes for our customers, partners, patients, and other stakeholders.

  7. Career Opportunities - Schrödinger

    Headquartered in New York City, Schrödinger has multiple offices around the world including the USA, the UK, Germany, India, and Japan.

  8. Explore our latest software - Schrödinger

    What’s new in Schrödinger Suite Release? We release new platform usability and technological improvements quarterly.

  9. Office Locations & Local Contact Information - Schrödinger

    Schrödinger is a global company with a collaborative spirit. View our office locations and local contact information below.

  10. Schrödinger Announces Discontinuation of SGR-2921 Program

    Aug 14, 2025 · Schrödinger, Inc. (Nasdaq: SDGR) today announced the discontinuation of the clinical development program for SGR-2921, its CDC7 inhibitor, which was being evaluated in …